New drug cuts chemotherapy side effect by over 60% in breast cancer patients
NCT ID NCT07671547
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tested whether Naderin, an immune-boosting drug, could prevent low white blood cell counts in 79 women with breast cancer receiving first-line chemotherapy. Participants either received Naderin alongside chemotherapy or chemotherapy alone. The results showed that only 14% of those taking Naderin developed low white blood cell counts, compared to 39% in the control group, suggesting Naderin may help reduce this common side effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Naderin (sodium deoxyribonucleate)
What this could lead to
If it works, this could help breast cancer patients avoid low white blood cell counts during chemotherapy and complete their treatment with fewer interruptions.
What could go wrong
This is a small, completed Phase 2/3 trial with only 79 participants. The results may not apply to all breast cancer patients or other chemotherapy regimens. Naderin is not widely available or approved for this use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.